Intravitreal Implant(유리체강내 임플란트)란 무엇입니까?
Intravitreal Implant 유리체강내 임플란트 - Dose escalation and increasing molecular weight of drugs, intravitreal implants and nanoparticles, hydrogels, combined systems, and port delivery systems are presently under preclinical and clinical investigations. [1] Intravitreal implant and anti-VEGF injections were performed following a prn regimen. [2] Intravitreal implantation of Ozurdex (Allergan Inc. [3] AIM To report the effectiveness of intravitreal implantation of dexamethasone implant (Ozurdex) after phacoemulsification and intraocular lens implantation in refractory uveitis patients. [4] Aim: To develop and validate a fit for purpose method for the simultaneous determination of dexamethasone and its major metabolite, 6β-hydroxydexamethasone, in rabbit plasma and ocular matrices to measure the in vivo release and distribution profile of dexamethasone from intravitreal implants. [5] Suprachoroidal, subretinal, and intravitreal implants can be monitored for length, diameter, and volume using cSLO and OCT imaging. [6] Intraocular/Intravitreal implants constitute a relatively new method to treat eye diseases successfully due to the possibility of releasing drugs in a controlled and prolonged way. [7] An atypical case of acute posterior multifocal placoid pigment epitheliopathy with a clear reappearance of the ellipsoid layer of the retina after Ozurdex® intravitreal implantation is presented. [8] BACKGROUND/PURPOSE To describe management of anterior migration of a fluocinolone acetonide(FAc) intravitreal implant. [9] 19 mg fluocinolone acetonide (FAc) intravitreal implant in this cohort with up to 3 years of follow-up. [10] Currently available corticosteroids include triamcinolone acetonide (TA), the dexamethasone (DEX) intravitreal implant, and the fluocinolone acetonide (FA) intravitreal implant. [11] Steroid-induced ocular hypertension (SIOH), which cannot be regulated by topical antiglaucoma agents, is a rare complication after intravitreal implantation of diverse cortisone derivatives. [12]약물, 유리체내 임플란트 및 나노입자, 하이드로겔, 복합 시스템, 포트 전달 시스템의 용량 증량 및 분자량 증가는 현재 전임상 및 임상 조사 중에 있습니다. [1] 유리체강내 임플란트 및 항-VEGF 주사는 prn 요법에 따라 수행되었습니다. [2] Ozurdex의 유리체강내 이식(Allergan Inc. [3] 겨냥하다 난치성 포도막염 환자에서 수정체 유화술 및 안구 내 수정체 이식 후 덱사메타손 임플란트(Ozurdex)의 유리체내 이식의 효과를 보고합니다. [4] 목표: 토끼 혈장 및 안구 매트릭스에서 덱사메타손과 주요 대사산물인 6β-하이드록시덱사메타손을 동시에 측정하여 유리체내 임플란트에서 덱사메타손의 생체 내 방출 및 분포 프로파일을 측정하기 위한 목적에 맞는 방법을 개발하고 검증합니다. [5] 맥락막상, 망막하 및 유리체내 임플란트는 cSLO 및 OCT 영상을 사용하여 길이, 직경 및 부피에 대해 모니터링할 수 있습니다. [6] 안내/유리체내 임플란트는 통제되고 장기간에 걸쳐 약물을 방출할 가능성으로 인해 안구 질환을 성공적으로 치료하는 비교적 새로운 방법을 구성합니다. [7] Ozurdex® 유리체강내 이식 후 망막의 타원체 층이 명확하게 다시 나타나는 급성 후방 다초점 기원판 색소 상피병증의 비정형 증례를 제시합니다. [8] 배경/목적 Fluocinolone acetonide(FAc) 유리체강내 임플란트의 전방 이동 관리를 설명합니다. [9] 이 코호트에 19mg 플루오시놀론 아세토나이드(FAc) 유리체강 내 임플란트를 사용하고 최대 3년까지 추적 관찰합니다. [10] 현재 사용 가능한 코르티코스테로이드에는 트리암시놀론 아세토나이드(TA), 덱사메타손(DEX) 유리체강내 임플란트 및 플루오시놀론 아세토나이드(FA) 유리체내 임플란트가 있습니다. [11] 국소 항녹내장제로 조절할 수 없는 스테로이드 유발 안구 고혈압(SIOH)은 다양한 코르티손 유도체를 유리체강내 이식한 후 발생하는 드문 합병증입니다. [12]
diabetic macular edema 당뇨병성 황반부종
Fluocinolone acetonide intravitreal implant is approved for the treatment of nonanterior noninfectious uveitis and diabetic macular edema (ME), with an estimated therapeutic duration of 3 years. [1] Three‐year, randomized, sham‐controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. [2] Purpose The purpose was to assess the number and intervals of dexamethasone intravitreal implant (DEX) reinjections in a real-world setting for the treatment of diabetic macular edema (DME) and to determine the relationship with effectiveness and safety. [3] Purpose: To compare the efficacy, adverse effects, and treatment burden of two injectable corticosteroids, triamcinolone acetonide (Kenalog® or Triesence®) and the dexamethasone intravitreal implant (Ozurdex®), for treating diabetic macular edema (DME). [4] Aim To investigate late changes in peripheral ischemia in patients affected by diabetic macular edema (DME) and treated with repeated dexamethasone (DEX) intravitreal implants over a 1-year period. [5] Purpose: To compare the results of early versus late switch to the dexamethasone intravitreal implant Ozurdex® in patients with diabetic macular edema who had a poor response to vascular endothelial growth factor inhibitors. [6] ABSTRACT Purpose: To assess changes in aqueous humor (AH) levels of cytokines following dexamethasone intravitreal implant (DEX) injection for diabetic macular edema (DME). [7] Objectives: Despite being approved and effective, steroids, and especially dexamethasone intravitreal implants, still have a poorly-defined role in management of diabetic macular edema. [8] Purpose To determine whether baseline cytokine aqueous humor (AH) levels are associated with diabetic macular edema (DME) anatomic response to dexamethasone intravitreal implant (DEX) injection. [9] Objective: To compare the effectiveness and safety of the fluocinolone acetonide (FAc) intravitreal implant between the observational Iluvien Clinical Evidence study in the United Kingdom (ICE-UK) and the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) randomized controlled trials (RCTs) in people with diabetic macular edema (DME). [10] 2 µg/day fluocinolone acetonide [FAc] intravitreal implant (ILUVIEN®) in patients with persistent or recurrent diabetic macular edema (DME) and 6–18 months of follow-up. [11] 7 mg dexamethasone intravitreal implant (Ozurdex, Allergan), (DEX) to treat and manage diabetic macular edema (DME); we also summarize available case reports and review the literature regarding persistent vitreous hemorrhage. [12] Objective: To gain information about multiple dexamethasone intravitreal implant (DEX-I) injections in diabetic macular edema (DME) eyes in real-life clinical settings. [13]Fluocinolone acetonide 유리체강내 임플란트는 비전방 비감염성 포도막염 및 당뇨병성 황반부종(ME) 치료에 승인되었으며 예상 치료 기간은 3년입니다. [1] 당뇨병성 황반 부종이 있는 환자를 대상으로 한 덱사메타손 유리체강내 임플란트의 3년, 무작위, 가짜 대조 시험. [2] nan [3] nan [4] 목적 당뇨병성 황반부종(DME)의 영향을 받고 1년 동안 반복된 덱사메타손(DEX) 유리체강내 임플란트로 치료받은 환자에서 말초 허혈의 후기 변화를 조사하는 것입니다. [5] 목적: 혈관내피세포 성장인자 억제제에 반응이 좋지 않은 당뇨병성 황반부종 환자에서 dexamethasone 유리체강내 임플란트 Ozurdex®로의 조기 전환과 후기 전환의 결과를 비교하고자 한다. [6] nan [7] nan [8] nan [9] nan [10] nan [11] nan [12] nan [13]
retinal vein occlusion 망막 정맥 폐색
Purpose To supplement established efficacy and safety data, this analysis evaluated the real-world use of dexamethasone (DEX) intravitreal implant 700 µg for retinal vein occlusion (RVO)-related macular edema in an Asian population and baseline factors potentially associated with DEX implant efficacy. [1] 7 mg intravitreal implant (Ozurdex®) versus dexamethasone alone in providing better visual acuity in eyes with macular edema (ME) secondary to retinal vein occlusion (RVO). [2] We present a unique case of endophthalmitis with Staphylococcus lugdunensis following dexamethasone intravitreal implant for branch retinal vein occlusion associated with cystoid macular edema. [3] Case report: The authors report a case with non-ischemic central retinal vein occlusion that was successfully treated with a single sustained-release fluocinolone acetonide intravitreal implant. [4]목적 확립된 효능 및 안전성 데이터를 보완하기 위해, 이 분석은 아시아 인구에서 망막 정맥 폐쇄(RVO) 관련 황반 부종에 대한 덱사메타손(DEX) 유리체내 임플란트 700 µg의 실제 사용과 DEX 임플란트 효능과 잠재적으로 관련된 기준 요소를 평가했습니다. . [1] 7 mg 유리체강내 임플란트(Ozurdex®) 대 덱사메타손 단독은 망막 정맥 폐색(RVO)에 따른 황반 부종(ME)이 있는 눈에서 더 나은 시력을 제공합니다. [2] 우리는 낭포 황반 부종과 관련된 망막 분지 정맥 폐쇄에 대한 덱사메타손 유리체강내 임플란트 후 포도상구균 lugdunensis에 의한 안구내염의 독특한 증례를 제시합니다. [3] 증례 보고: 저자들은 단일 서방형 플루오시놀론 아세토나이드 유리체강내 임플란트로 성공적으로 치료된 비허혈성 중심 망막 정맥 폐색 증례를 보고합니다. [4]
19 mg fluocinolone 19mg 플루오시놀론
19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema (UME) was assessed on twenty-six patients (34 eyes) with non-infectious UME between 2013 and 2020, in a mean follow-up of 18 ± 19. [1] 19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. [2] 19 mg fluocinolone acetonide intravitreal implant was deemed an appropriate step-up treatment option. [3]19mg 플루오시놀론 아세토나이드(FAc) 유리체강내 임플란트(ILUVIEN)는 2013년에서 2020년 사이에 비감염성 UME가 있는 26명의 환자(34안)를 대상으로 평가되었습니다. 18 ± 19의 후속 조치. [1] 만성 당뇨병성 황반부종(DMO)에 대한 19mg Fluocinolone Acetonide(FAc) 유리체강내 임플란트, 이러한 결과를 당뇨병성 황반부종(FAME) 연구에 대한 Fluocinolone Acetonide와 비교합니다. [2] nan [3]
endothelial growth factor
Background: This meta-analysis compared the efficacy and safety of dexamethasone intravitreal implant (DEX) and anti-vascular endothelial growth factor (anti-VEGF) in the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). [1] Objectives To estimate the costs and healthcare resources of patients with diabetic macular oedema (DME) who received intravitreal antivascular endothelial growth factor (anti-VEGF) agents or a dexamethasone intravitreal implant (DEX-implant) in Korea. [2]배경: 이 메타 분석은 망막 분지 정맥 폐색(BRVO)에 따른 황반 부종(ME) 치료에서 덱사메타손 유리체내 임플란트(DEX)와 항혈관 내피 성장 인자(항-VEGF)의 효능과 안전성을 비교했습니다. [1] 목적 한국에서 유리체강내 항혈관내피성장인자(anti-VEGF) 제제 또는 덱사메타손 유리체강내 임플란트(DEX-implant)를 투여받은 당뇨병성 황반부종(DME) 환자의 비용 및 의료 자원 추정. [2]
branch retinal vein 가지 망막 정맥
Background This study evaluated the effects of dexamethasone intravitreal implant on treatment-naïve branch retinal vein occlusion (BRVO)-induced macular edema (ME), and the risk factors for earlier repeated treatment. [1]배경 이 연구는 치료 경험이 없는 분지 망막 정맥 폐색(BRVO) 유발 황반 부종(ME)에 대한 덱사메타손 유리체내 임플란트의 효과와 조기 반복 치료의 위험 인자를 평가했습니다. [1]
vascular endothelial growth 혈관 내피 성장
2 µg daily fluocinolone acetonide intravitreal implant), who had suboptimal outcomes with first-line vascular endothelial growth-factor inhibitors and other DME therapies. [1]2 µg 매일 플루오시놀론 아세토나이드 유리체강내 임플란트), 1차 혈관 내피 성장 인자 억제제 및 기타 DME 요법으로 차선의 결과를 보였습니다. [1]
Dexamethasone Intravitreal Implant 덱사메타손 유리체강내 임플란트
The first patient was further treated with a dexamethasone intravitreal implant (Ozurdex®) owing to the side effects of methylprednisolone. [1] Purpose To evaluate the safety and efficacy of dexamethasone intravitreal implant 0. [2] The treatment regimen for Dexamethasone intravitreal implant (DEXii) should be pro-re-nata with bi-monthly or quarterly monitoring visits (with a scheduled visit at 6–8 weeks after DEXii for intraocular pressure control). [3] Methods: Pars plana vitrectomy (PPV) was performed, with an accurate forceps-assisted ILM removal, hemorrhage aspiration, and a dexamethasone intravitreal implant injection at the end of the surgery. [4] Purpose: To investigate the efficacy and safety of dexamethasone intravitreal implant in the treatment of relapsing posterior uveitis in patients with chronic recurrent VKH disease. [5] We evaluated the efficacy of combination of Dexamethasone intravitreal implant (DXI) and anti-VEGF therapy in eyes resistant to anti-VEGF monotherapy. [6] Ozurdex is a dexamethasone intravitreal implant used for the treatment of macular oedema. [7] Three‐year, randomized, sham‐controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. [8] The purpose of our study was to assess the outcome of VKH disease with bilateral panuveitis treated with dexamethasone intravitreal implant. [9] Purpose The purpose was to assess the number and intervals of dexamethasone intravitreal implant (DEX) reinjections in a real-world setting for the treatment of diabetic macular edema (DME) and to determine the relationship with effectiveness and safety. [10] The patient was then treated with a dexamethasone intravitreal implant 0. [11] Background This study evaluated the effects of dexamethasone intravitreal implant on treatment-naïve branch retinal vein occlusion (BRVO)-induced macular edema (ME), and the risk factors for earlier repeated treatment. [12] Purpose To describe a case of Cytomegalovirus (CMV) Retinitis in an immunocompetent patient following Dexamethasone Intravitreal Implant (DII). [13] Aim To evaluate the effectiveness of dexamethasone intravitreal implant 0. [14] A combination of dexamethasone intravitreal implant with chlorambucil therapy can be an effective and promising regimen in inducing and maintaining remission in refractory serpiginous choroiditis patients who fail a combination of systemic corticosteroid and chlorambucil therapy. [15] PURPOSE To assess the feasibility and clinical effectiveness of dexamethasone intravitreal implant 0. [16] In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. [17] PURPOSE To analyse the morpho-functional outcomes of dexamethasone intravitreal implant (Ozurdex) injected after lens surgery in diabetic patients with coexisting cataract and macular oedema. [18] Methods: This was a single-center, retrospective, observational, cohort study based on the data retrieved from the medical records of the patients with ME who were administered with dexamethasone intravitreal implant during 2013 to 2018. [19] Purpose: To compare the efficacy, adverse effects, and treatment burden of two injectable corticosteroids, triamcinolone acetonide (Kenalog® or Triesence®) and the dexamethasone intravitreal implant (Ozurdex®), for treating diabetic macular edema (DME). [20] The man presented with a 2-week history of left eye floaters and irritation 10 weeks following dexamethasone intravitreal implant [Ozurdex] injection for neovascular age-related macular degeneration (AMD). [21] Objective This study is aimed at identifying potential therapeutic targets in RVO with integrative bioinformatic analysis and compares the OCTA characteristics alterations in patients with RVO-ME receiving injection of dexamethasone intravitreal implant. [22] PATIENTS AND METHODS Six dexamethasone intravitreal implants were injected into a calibrated ex vivo water bath. [23] We present a unique case of endophthalmitis with Staphylococcus lugdunensis following dexamethasone intravitreal implant for branch retinal vein occlusion associated with cystoid macular edema. [24] Background: This meta-analysis compared the efficacy and safety of dexamethasone intravitreal implant (DEX) and anti-vascular endothelial growth factor (anti-VEGF) in the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). [25] Purpose: To compare the results of early versus late switch to the dexamethasone intravitreal implant Ozurdex® in patients with diabetic macular edema who had a poor response to vascular endothelial growth factor inhibitors. [26] ABSTRACT Purpose: To assess changes in aqueous humor (AH) levels of cytokines following dexamethasone intravitreal implant (DEX) injection for diabetic macular edema (DME). [27] Dexamethasone intravitreal implant has demonstrated efficacy in the treatment of DME resistant to anti-VEGF therapy and in vitrectomized eyes. [28] BackgroundDiabetic macular edema (DME) can be treated with different alternatives, among them Dexamethasone intravitreal implant 0. [29] Dexamethasone intravitreal implant (OZURDEX®; Allergan, Inc. [30] Objectives To estimate the costs and healthcare resources of patients with diabetic macular oedema (DME) who received intravitreal antivascular endothelial growth factor (anti-VEGF) agents or a dexamethasone intravitreal implant (DEX-implant) in Korea. [31] METHODS: From the Health Information System of the Lazio Region were identified all subjects who, in the 2010-2016 period, had received at least one prescription for dexamethasone intravitreal implant (i. [32] Objectives: Despite being approved and effective, steroids, and especially dexamethasone intravitreal implants, still have a poorly-defined role in management of diabetic macular edema. [33] The study population was sham-treated patients (n = 350) in the 3-year MEAD registration study of dexamethasone intravitreal implant for treatment of DME. [34] The purpose of the study was to report a case of migration of a dexamethasone intravitreal implant (Ozurdex®) into anterior chamber and review the literature pertaining to the anterior chamber migration of implant. [35] They underwent unilateral dexamethasone intravitreal implantation. [36] Purpose To determine whether baseline cytokine aqueous humor (AH) levels are associated with diabetic macular edema (DME) anatomic response to dexamethasone intravitreal implant (DEX) injection. [37] The LC thickness of CRVO patients was evaluated one month after dexamethasone intravitreal implant (Ozurdex) injection. [38] Here we reported a rare case of the implantation of a dexamethasone intravitreal implant (DEX) in which decreased retinal vessel density (VD) was found by optical coherence tomography angiography (OCTA). [39] In this context, recent guidelines suggest the use of corticosteroids, and in particular dexamethasone intravitreal implant, as a well-tolerated and efficacious first-line treatment in patients with high CV risk, such as a history of or recent major CV events. [40] However, this case shows peripheral retinal defects in a vitrectomized eye with abutting dexamethasone intravitreal implant without a flap, operculum, or other evidence of traction, developing 3 months after insertion, excluding the chance of injury from impact. [41] PURPOSE To present a case of endophthalmitis caused by Abiotrophia defectiva after repeated injections of dexamethasone intravitreal implant (Ozurdex), in a patient already on systemic immunosuppressive therapy, and discuss the management of this challenging situation. [42] 7 mg dexamethasone intravitreal implant (Ozurdex, Allergan), (DEX) to treat and manage diabetic macular edema (DME); we also summarize available case reports and review the literature regarding persistent vitreous hemorrhage. [43] Objective: To gain information about multiple dexamethasone intravitreal implant (DEX-I) injections in diabetic macular edema (DME) eyes in real-life clinical settings. [44] We describe the use of a dexamethasone intravitreal implant for symptomatic management in a case of X-linked (juvenile) retinoschisis (XLRS). [45] The patient was treated with dexamethasone intravitreal implant. [46]첫 번째 환자는 메틸프레드니솔론의 부작용으로 인해 덱사메타손 유리체내 임플란트(Ozurdex®)로 추가 치료를 받았습니다. [1] 목적 덱사메타손 유리체강내 임플란트 0의 안전성과 유효성을 평가하고자 하였다. [2] nan [3] 방법: PPV(pars plana vitrectomy)를 시행하였으며 수술 종료 시 정확한 겸자를 이용한 ILM 제거, 출혈 흡인 및 dexamethasone 유리체강내 임플란트 주입을 시행하였다. [4] nan [5] nan [6] nan [7] 당뇨병성 황반 부종이 있는 환자를 대상으로 한 덱사메타손 유리체강내 임플란트의 3년, 무작위, 가짜 대조 시험. [8] nan [9] nan [10] nan [11] 배경 이 연구는 치료 경험이 없는 분지 망막 정맥 폐색(BRVO) 유발 황반 부종(ME)에 대한 덱사메타손 유리체내 임플란트의 효과와 조기 반복 치료의 위험 인자를 평가했습니다. [12] nan [13] nan [14] nan [15] nan [16] nan [17] nan [18] nan [19] nan [20] nan [21] nan [22] 환자 및 방법 6개의 덱사메타손 유리체내 임플란트를 보정된 생체외 수조에 주입했습니다. [23] 우리는 낭포 황반 부종과 관련된 망막 분지 정맥 폐쇄에 대한 덱사메타손 유리체강내 임플란트 후 포도상구균 lugdunensis에 의한 안구내염의 독특한 증례를 제시합니다. [24] 배경: 이 메타 분석은 망막 분지 정맥 폐색(BRVO)에 따른 황반 부종(ME) 치료에서 덱사메타손 유리체내 임플란트(DEX)와 항혈관 내피 성장 인자(항-VEGF)의 효능과 안전성을 비교했습니다. [25] 목적: 혈관내피세포 성장인자 억제제에 반응이 좋지 않은 당뇨병성 황반부종 환자에서 dexamethasone 유리체강내 임플란트 Ozurdex®로의 조기 전환과 후기 전환의 결과를 비교하고자 한다. [26] nan [27] nan [28] nan [29] nan [30] 목적 한국에서 유리체강내 항혈관내피성장인자(anti-VEGF) 제제 또는 덱사메타손 유리체강내 임플란트(DEX-implant)를 투여받은 당뇨병성 황반부종(DME) 환자의 비용 및 의료 자원 추정. [31] nan [32] nan [33] nan [34] nan [35] nan [36] nan [37] nan [38] nan [39] nan [40] nan [41] nan [42] nan [43] nan [44] nan [45] nan [46]
Acetonide Intravitreal Implant 아세토나이드 유리체강내 임플란트
Objective To evaluate the effectiveness and safety of fluocinolone acetonide intravitreal implant (0. [1] Fluocinolone acetonide intravitreal implant is approved for the treatment of nonanterior noninfectious uveitis and diabetic macular edema (ME), with an estimated therapeutic duration of 3 years. [2] 2 µg daily fluocinolone acetonide intravitreal implant), who had suboptimal outcomes with first-line vascular endothelial growth-factor inhibitors and other DME therapies. [3] 19 mg fluocinolone acetonide intravitreal implant was deemed an appropriate step-up treatment option. [4] METHOD Between 2013 and 2018, 27 consecutive eyes of 25 patients with chronic/refractory DME were treated with a fluocinolone acetonide intravitreal implant. [5] 19-mg fluocinolone acetonide intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema. [6] The patient was treated with bilateral fluocinolone acetonide intravitreal implants. [7] The National Institute for Health and Care Excellence (NICE) invited Alimera Sciences, the company manufacturing fluocinolone acetonide intravitreal implant (FAc) 0. [8] PURPOSE To report the persistence of choroidal lesions despite fluocinolone acetonide intravitreal implants and their resolution with oral prednisone treatment. [9] Case report: The authors report a case with non-ischemic central retinal vein occlusion that was successfully treated with a single sustained-release fluocinolone acetonide intravitreal implant. [10]목적 Fluocinolone acetonide 유리체강내 임플란트(0. [1] Fluocinolone acetonide 유리체강내 임플란트는 비전방 비감염성 포도막염 및 당뇨병성 황반부종(ME) 치료에 승인되었으며 예상 치료 기간은 3년입니다. [2] 2 µg 매일 플루오시놀론 아세토나이드 유리체강내 임플란트), 1차 혈관 내피 성장 인자 억제제 및 기타 DME 요법으로 차선의 결과를 보였습니다. [3] nan [4] nan [5] 비감염성 포도막염 황반부종의 치료에 19mg 플루오시놀론 아세토나이드 유리체강내 임플란트(ILUVIEN). [6] 환자는 양측 Fluocinolone acetonide 유리체강내 임플란트로 치료되었습니다. [7] nan [8] nan [9] 증례 보고: 저자들은 단일 서방형 플루오시놀론 아세토나이드 유리체강내 임플란트로 성공적으로 치료된 비허혈성 중심 망막 정맥 폐색 증례를 보고합니다. [10]
Dex Intravitreal Implant Dex 유리체강내 임플란트
METHODS This was an audit retrospective review of medical records of patients with DME who switched to the DEX intravitreal implant. [1] All the patients were treated with DEX intravitreal implant, showing a decrease in CMT and a stabilization of visual acuity. [2] This paper is aimed to provide a review of the research and application of DEX intravitreal implant in the treatment of macular edema in recent years, and provide a new option for the treatment of these clinical refractory diseases. [3]행동 양식 이것은 DEX 유리체강내 임플란트로 전환한 DME 환자의 의료 기록에 대한 감사 후향적 검토였습니다. [1] 모든 환자에서 DEX 유리체강내 임플란트 치료를 시행하였고 CMT 감소와 시력 안정화를 보였다. [2] nan [3]
Release Intravitreal Implant
Corticosteroid slow-release intravitreal implants as well as anti-TNF and anti-IL-6 biologic drugs have been the cornerstone of these medical advances. [1] , Irvine, CA, USA), a sustained-release intravitreal implant of 0. [2]코르티코스테로이드 서방성 유리체내 임플란트와 항-TNF 및 항-IL-6 생물학적 약물은 이러한 의학적 발전의 초석이 되었습니다. [1] , Irvine, CA, USA), 0의 서방성 유리체내 임플란트. [2]
Fac Intravitreal Implant Fac 유리체강내 임플란트
2 µg/day FAc intravitreal implant with three-year follow-up expected. [1] METHODS A retrospective, observational, single-center, 12-month audit study, where 22 pseudophakic eyes (22 patients) with DME were treated with the FAc intravitreal implant according to licensed UAE indications. [2]2 µg/day FAc 유리체강내 임플란트, 3년 추적 관찰이 예상됩니다. [1] 행동 양식 DME가 있는 22명의 pseudophakic 눈(22명의 환자)이 허가된 UAE 적응증에 따라 FAc 유리체강내 임플란트로 치료된 후향적, 관찰, 단일 센터, 12개월 감사 연구입니다. [2]
intravitreal implant injection
Methods: Pars plana vitrectomy (PPV) was performed, with an accurate forceps-assisted ILM removal, hemorrhage aspiration, and a dexamethasone intravitreal implant injection at the end of the surgery. [1] One month after intravitreal implant injection the visual acuity in the patient's eye improved from 0. [2]방법: PPV(pars plana vitrectomy)를 시행하였으며 수술 종료 시 정확한 겸자를 이용한 ILM 제거, 출혈 흡인 및 dexamethasone 유리체강내 임플란트 주입을 시행하였다. [1] nan [2]